在MITA/STING功能获取突变体中的额外位点突变消除了自身免疫SAVI表型,并指导治疗策略
Fang-Xu Li1, Sheng Liu2, Zhi-Dong Zhang1
1Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Cancer Center, Renmin Hospital of Wuhan University, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, College of Life Sciences, State Key Laboratory of Metabolism and Regulation in Complex Organisms, State Key Laboratory of Virology and Biosafety, Hubei Provincial Research Center for Basic Biological Sciences, Wuhan University, Wuhan 430071, Hubei, China.
在MITA/STING中获得功能突变会导致SAVI. 这项研究显示,Lys150突变抑制了自发MITA激活和iRhom2相互作用,为SAVI提供了治疗标.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 发病于婴儿期的刺痛相关血管病变 (SAVI) 是一种自身免疫性疾病.
- 在MITA/STING中获得功能突变 (GOFs),特别是MITAN154S和MITAV155M,是SAVI的主要原因.
- 目前尚不清楚MITA GOFs自发激活的确切机制.
研究的目的:
- 阐明SAVI中MITAGOFs自发激活的机制.
- 调查Lys150突变在MITA GOF活动中的作用.
- 为了确定SAVI的潜在治疗策略.
主要方法:
- 使用小鼠模型 (MITAK150N/N153S) 来研究SAVI表型.
- 研究了MITA-iRhom2相互作用和ER-到Golgi转移.
- 进行了MITANS形状的结构研究.
- 设计并测试了一种SAVI抑制性 (SIP).
主要成果:
- 一种Lys150突变影响了MITA链区域的GOF活动,并消除了小鼠中的SAVI表型.
- MITA GOFs与iRhom2构成关联,促进自发的ER-to-Golgi转移.
- 这种相互作用和转位被Lys150突变抑制.
- cGAMP与MITANS结合会触发转位和下游基因表达.
- 一种新的SAVI抑制性 (SIP) 在体内有效抑制MITA GOF活性和SAVI表型.
结论:
- 一个以前未被描述的自发MITA GOF激活机制涉及iRhom2关联和ER-to-Golgi转位.
- 莱斯150突变作为MITA GOF激活的负调节者.
- 一种针对MITA-iRhom2相互作用的SAVI抑制性体显示了SAVI的治疗潜力.
相关概念视频
Conjugate Addition (1,4-Addition) vs Direct Addition (1,2-Addition)
Conjugate addition results in a thermodynamically stable product. The reaction retains the stronger C=O bond at the expense of the weaker C=C π bond. The process is slow as the β carbon is less electrophilic than the carbonyl carbon.
Direct addition products are...
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Gain
Gain:
Suppose Vin is the input and Vout is the output signal to a circuit.
Viral Mutations


